SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63.

Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel.
Molecular and Cellular Biology (Impact Factor: 5.04). 02/2011; 31(8):1679-89. DOI: 10.1128/MCB.01072-10
Source: PubMed

ABSTRACT The transcription factor p53 functions not only to suppress tumorigenesis but also to maintain normal development and homeostasis. Although p53 was implicated in different aspects of fertility, including spermatogenesis and implantation, the mechanism underlying p53 involvement in spermatogenesis is poorly resolved. In this study we describe the identification of a spermatogenesis-associated gene, SPATA18, as a novel p53 transcriptional target and show that SPATA18 transcription is induced by p53 in a variety of cell types of both human and mouse origin. p53 binds a consensus DNA motif that resides within the first intron of SPATA18. We describe the spatiotemporal expression patterns of SPATA18 in mouse seminiferous tubules and suggest that SPATA18 transcription is regulated in vivo by p53. We also demonstrate the induction of SPATA18 by p63 and suggest that p63 can compensate for the loss of p53 activity in vivo. Our data not only enrich the known collection of p53 targets but may also provide insights on spermatogenesis defects that are associated with p53 deficiency.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is well accepted that expression of mutant p53 involves the gain of oncogenic specific activities accentuating malignant phenotype. Depending on the specific cancer type mutant p53 can contribute to either the early or late events of the multiphase process underlying the transformation of a normal cell into cancerous one. This multi factorial system is evident in about 50% of human cancers. Mutant p53 was shown to interfere with a variety of cellular functions that are leading to augmented cell survival, cellular plasticity, aberration of DNA repair machinery and others. All culminate in the acquisition of drug resistance often seen in cancer cells. Interestingly, drug resistance was also suggested to be associated with cancer stem cells, which reside within growing tumors. The notion that p53 plays a regulatory role in the life of stem cells coupled with the observations that p53 mutations may contribute to the evolvement of cancer stem cells, makes it challenging to speculate that drug resistance and cancer recurrence are mediated by cancer stem cells expressing mutant p53.
    Carcinogenesis 03/2014; DOI:10.1093/carcin/bgu073 · 5.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: TP53 is a tumor-suppressor gene which is involved in multiple pathways including apoptosis, transcriptional regulation, and cell cycle control. To analyze whether the TP53 gene Arg72Pro polymorphism (rs1042522) is responsible for susceptibility to idiopathic infertility in southeast Chinese Han males, we used the PCR restriction fragment length polymorphism technique to detect the genotype distribution of 361 infertile men (including 212 with non-obstructive azoospermia and 149 with severe oligozoospermia) in comparison with 384 fertile controls. Genotyping was confirmed by DNA sequencing from randomly selected samples. The frequency of rs1042522 indicated an association with risk of idiopathic male infertility under a dominant mode (GG + GC genotypes vs. CC genotype, P = 0.013; χ(2) = 6.169; OR = 1.581; 95%CI = 1.1-2.272; df = 1). Comparison of the allele frequencies revealed a significantly higher incidence of Arg allele among azoospermia group compared with controls (P = 0.001; χ(2) =10.864; OR = 1.502; 95%CI = 1.177-1.917; df = 1). Our data suggest that the Arg allele was related only to azoospermia, not to severe oligozoospermia (P = 0.133; χ(2) = 2.261; OR = 1.23; 95%CI = 0.939-1.611; df = 1). This study indicated that the TP53 gene Arg72Pro polymorphism of the spermatogenic pathway may be associated with idiopathic infertility in southeast Chinese Han males.
    Systems biology in reproductive medicine 12/2013; 59(6):342-346. DOI:10.3109/19396368.2013.818743 · 1.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in the TP53 tumor suppressor gene occur in half of all human cancers, indicating its critical importance in inhibiting cancer development. Despite extensive studies, the mechanisms by which mutant p53 enhances tumor progression remain only partially understood. Here, using data from The Cancer Genome Atlas (TCGA), genomic and transcriptomic analyses were performed on 2256 tumors from ten human cancer types. We show that tumors with TP53 mutations have altered gene expression profiles compared to tumors retaining two wildtype TP53 alleles. Among 113 known p53 upregulated target genes identified from cell culture assays, ten were consistently upregulated in at least 8 of 10 cancer types that retain both copies of wildtype TP53. RPS27L, CDKN1A (p21(CIP1) ), and ZMAT3 were significantly upregulated in all ten cancer types retaining wildtype TP53. Using this p53-based expression analysis as a discovery tool, we used cell-based assays to identify five novel p53 target genes from genes consistently upregulated in wildtype p53 cancers. Global gene expression analyses revealed that cell cycle regulatory genes and transcription factors E2F1, MYBL2, and FOXM1 were disproportionately upregulated in many TP53 mutant cancer types. Finally, over 93% of tumors with a TP53 mutation exhibited greatly reduced wildtype p53 messenger expression due to loss of heterozygosity or copy neutral loss of heterozygosity, supporting the concept of p53 as a recessive tumor suppressor. The data indicate that tumors with wildtype TP53 retain some aspects of p53-mediated growth inhibitory signaling through activation of p53 target genes and suppression of cell cycle regulatory genes.
    The Journal of Pathology 04/2014; 232(5). DOI:10.1002/path.4321 · 7.33 Impact Factor


Available from
Jun 1, 2014